Financial Data and Key Metrics Changes - The company's net sales for Q1 2025 were $1.2 billion, down 3.4% compared to Q1 2024, but showed a constant currency growth of 1.4% year over year [10][27] - Adjusted EBITDA for Q1 was $165 million, exceeding guidance, with adjusted EBITDA margins at 13.5%, up 260 basis points year over year [28] - The total leverage ratio was reduced to three times as of March 31, achieving the target set for the end of 2025 nine months ahead of schedule [11][31] Business Line Data and Key Metrics Changes - The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth [12] - The company reported a gross profit margin improvement to 78.3%, up 80 basis points compared to Q1 2024, driven by pricing actions and reduced input costs [28] Market Data and Key Metrics Changes - In Latin America, net sales were down 4% on a reported basis but up 11% on a local currency basis, with a 4% increase in volumes [33] - EMEA net sales were down 2% year over year on a reported basis, while up 3% on a local currency basis, with a 5% decline in volume [34] - North America saw a 4% decrease in net sales year over year, primarily due to an 8% reduction in volumes [35] Company Strategy and Development Direction - The company aims to lead in the health and wellness economy by leveraging its distributor network and enhancing its product offerings through technology and personalization [7][8] - Recent acquisitions of Protocol Health, Pruvit Ventures, and Link Biosciences are intended to strengthen the company's position in personalized health solutions [13][21] - The focus will be on innovation, operational excellence, and sustainable growth rather than just short-term gains [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to adapt to changing consumer expectations and the gig economy, viewing these changes as opportunities for growth [6][8] - The company expects FX to remain a significant headwind for the remainder of 2025, impacting both net sales and adjusted EBITDA [40][43] - The outlook for Q2 2025 includes expected net sales to range from down 3.5% to up 0.5% year over year, with a constant currency basis expectation of down 0.5% to up 3.5% [41][44] Other Important Information - The company plans to launch a beta version of the Protocol platform in July 2025, with a commercial release planned for Q4 2025 [17][18] - The total cash consideration paid for recent acquisitions was $25.5 million, with contingent payments of up to $5 million based on successful launches [39] Q&A Session Summary Question: Can you expand on the monetization strategy of Protocol? - Management indicated that it is early to discuss ROI, but the digital platform aims to support product consumption and distributor engagement [47][50] Question: What is driving the sequential decline in distributor KPIs in North America? - Management noted that the quarter started strong but faced challenges in February, with expectations for improvement in Q2 [61][63] Question: Why was the constant currency sales guidance for 2025 reduced? - The reduction was primarily due to rolling in Q1 trends, with some weakness noted in Asia Pacific and cautious expectations for China [66][67] Question: What are the intentions for Link Biosciences? - The company aims to target both athletes and a more general audience, focusing on hyper-customization in health products [71][75] Question: Is there any additional CapEx associated with the recently acquired assets? - Management confirmed that the CapEx guidance was lowered due to underspending in Q1, but future months will include necessary expenditures for the acquisitions [92][93]

Medifast® Q1 2025 Earnings Supplement © 2025 Medifast, Inc. All Rights Reserved. This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expect" or other similar words or the negative of ...

Core Insights - LifeVantage Corporation successfully concluded its annual Global Convention in Salt Lake City, attended by over 2,000 Independent Consultants from around the world, focusing on business updates, product announcements, and training initiatives [1][2] Group 1: Product Launch and Expansion - The MindBody GLP-1 System™, previously available in the U.S. and Japan, is now launched for consumers in Europe, Mexico, Thailand, Australia, and New Zealand, marking a significant step in LifeVantage's global expansion [2] - Clinical study results revealed that both the MindBody GLP-1 System™ and MB System™ increased GLP-1 levels in the body by over 200 percent on average [3] Group 2: Sales Incentives and Events - The Drive ERA Q2 Sales Incentive doubles the bonus for Consultants reaching Senior Consultant 1 rank through customer enrollment and retention within the first three months [4] - LifeVantage announced the Executive Destination Trip for North American and European markets will take place in Thailand in 2026, along with the Activate Virtual Event on July 12 and the U.S. Momentum Academy scheduled for October 23-25 in Dallas, Texas [5] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, offering a range of health and wellness products designed to activate optimal health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and AXIO® nootropic energy drink mixes [6]

Core Insights - FitLife Brands, Inc. announced the resignation of Todd Ordal from its Board of Directors, effective April 25, 2025, as part of its commitment to refresh board composition in line with good corporate governance practices [1][4] - Shannon Pappas has been appointed as an independent director to fill the vacancy left by Mr. Ordal and will serve on the Audit, Compensation, and Nominating/Corporate Governance Committees [2] - Ms. Pappas brings over 25 years of experience in beauty, skincare, health, fitness, and consumer goods, with expertise in strategic growth, digital commerce, financial management, and market expansion [3] Company Developments - The Board of Directors expressed gratitude for Todd Ordal's contributions over his ten years of service, highlighting his role in strategy, marketing, and organizational effectiveness [4] - The company anticipates further changes to the Board composition in the coming years as part of its governance practices [5] - FitLife Brands is a developer and marketer of nutritional supplements and wellness products, offering over 250 products primarily online and through various retail locations [6]

Core Insights - USANA Health Sciences, Inc. announced that its Celavive Postbiotic Rescue Serum won a Good Housekeeping 2025 Beauty Award, highlighting the product's recognition in the beauty industry [1][2] Group 1: Product Recognition - The Celavive Postbiotic Rescue Serum is recognized for its ability to visibly reset and balance stressed-out, blemish-prone skin, featuring a lightweight formula with microbiome-friendly postbiotics and soothing botanicals [2] - Brent Neidig, USANA's chief commercial officer, expressed excitement over the award, attributing it to the hard work of the product and R&D teams [2] Group 2: Company Overview - USANA has been providing quality nutritional and lifestyle products for over 30 years, including award-winning supplements and innovative skincare lines [3] - The company emphasizes trust and quality in its offerings, encouraging consumers to explore its products through its website [3]

Company Achievements - Nature's Sunshine Products, Inc. has been awarded two Stevie® Awards at the 23rd Annual American Business Awards, including a Gold Stevie® Award for its 2023 Impact Report and a Silver Stevie® Award for Achievement in Product Innovation for its Chlorophyll Detoxifying Stick Packs [1][2][3] - The Gold Stevie® Award recognizes the company's achievements in responsible business practices and sustainability, while the Silver Stevie® Award highlights the innovative powdered form of chlorophyll that is more convenient than traditional liquid formats [2][3] Leadership and Commitment - The company's President and CEO, Terrence Moorehead, emphasized that these awards validate Nature's Sunshine's commitment to transparency and sustainability, reflecting the hard work of the entire team [3] - Tracee Comstock, Senior Vice President of Global Human Resources, noted that Nature's Sunshine demonstrates leadership in the natural products industry through high-quality supplements and responsible business practices [4] Industry Context - The American Business Awards is a premier business awards program in the U.S., with over 3,600 nominations submitted this year across various categories [5] - The awards ceremony will take place on June 10, 2025, at the Marriott Marquis Hotel in New York [5]

Core Insights - Nature's Sunshine Products, Inc. published its 2024 Impact Report, highlighting its commitment to social responsibility and sustainability [1][2] - The report outlines significant progress towards the company's 2025 environmental, social, and governance (ESG) goals [2] ESG Goals and Achievements - The company aims to protect and preserve the environment as part of its mission, with a focus on community engagement and workforce development [2][3] - Nature's Sunshine received TRUE Zero Waste Gold Certification for its U.S. Distribution centers in May 2024 [5] - The company has helped over 1 million women and children worldwide obtain nutrition through partnerships with organizations like Vitamin Angels and Feed My Starving Children [5] - The Spanish Fork manufacturing plant was converted to 100% renewable energy in 2022 [5] - Scope 1 & 2 greenhouse gas emissions have been reduced since 2021, with a goal of a 50% reduction by the end of 2025 [5] - Waste reduction at the manufacturing facility has reached 32% since 2021, with a target of 35% by the end of 2025 [5] Company Overview - Nature's Sunshine Products is a leading natural health and wellness company, marketing and distributing products in over 40 countries [7] - The company manufactures most of its products in state-of-the-art facilities to ensure high quality, safety, and efficacy [7]

Core Insights - Nature's Sunshine Products, Inc. has published its 2024 Impact Report, highlighting its commitment to social responsibility and sustainability [1][2] - The report outlines significant progress towards the company's 2025 environmental, social, and governance (ESG) goals, emphasizing environmental stewardship and community engagement [2][3] ESG Goals and Achievements - The company aims for a 50% reduction in Scope 1 & 2 greenhouse gas emissions by the end of 2025, having already reduced emissions since 2021 [5] - Nature's Sunshine has achieved a 32% reduction in waste at its manufacturing facility since 2021, with a goal of reaching a 35% reduction by the end of 2025 [5] - The company received TRUE Zero Waste Gold Certification for its U.S. Distribution centers in May 2024 [5] Community Engagement - Nature's Sunshine has partnered with organizations like Vitamin Angels and Feed My Starving Children to help over 1 million women and children worldwide obtain essential nutrition [5] - The company emphasizes workforce development initiatives that empower employees to contribute to sustainability efforts [2][3] Brand Alignment - The 2024 Impact Report is titled "Be More Earth," aligning with the company's recent marketing and brand campaign [4]

Financial Data and Key Metrics Changes - The company achieved high single-digit sales growth of 7% in Q1 2025, with adjusted earnings per share (EPS) growing 11% to $1.09, finishing at the high end of the guidance range [12][29][27] - Excluding COVID testing sales, sales growth was over 8% [12] - Gross margin expanded by 140 basis points, and operating margin increased by 130 basis points compared to the prior year [27][30] Business Line Data and Key Metrics Changes - Nutrition sales increased by 7%, driven by high single-digit growth in adult nutrition and double-digit growth in US pediatric nutrition [14] - Diagnostics sales declined by 5%, primarily due to a decrease in COVID-19 testing sales; core laboratory diagnostics grew 6.5% excluding China [15][29] - Established a new system, Alinity N, for molecular nucleic acid testing, representing a billion-dollar market opportunity [17] - Medical devices sales grew 12.5%, with continuous glucose monitors achieving over 20% growth [19] Market Data and Key Metrics Changes - Sales in the EPD segment increased by 8%, with double-digit growth in more than half of the key 15 markets [18] - The US dollar's weakening had a favorable impact on sales compared to exchange rates at the time of the previous earnings call [29] Company Strategy and Development Direction - The company is focused on navigating the complexities of a dynamic economic environment, including the impact of new tariff policies [10][11] - A diversified business model is emphasized as a strength, allowing the company to manage global challenges effectively [10] - The company plans to launch over 25 key new products over the next three years, contributing to sustained growth [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining guidance despite tariff impacts, estimating a few hundred million dollars in tariff-related costs for 2025 [45][46] - The company is actively assessing various scenarios to mitigate tariff impacts and is optimistic about its manufacturing network's flexibility [50][52] - Management expects the second half of 2025 to outperform the first half due to new product launches and improved market conditions [102] Other Important Information - The company is investing in R&D and expanding its portfolio in biosimilars and diagnostics, with a focus on enhancing its competitive position [18][90] - The company is also exploring M&A opportunities in medical devices and diagnostics while maintaining a disciplined approach to capital allocation [94][96] Q&A Session Summary Question: Impact of tariffs on full-year guidance - Management confirmed that tariffs will have a financial impact, estimating a few hundred million dollars for 2025, with a focus on mitigating strategies [45][46] Question: State of the EP franchise and Volt approval timeline - Management expressed optimism about the EP franchise, highlighting strong initial feedback for Volt and a potential US approval timeline in early 2026 [65][66] Question: Broader diagnostic strategy and M&A considerations - Management acknowledged challenges in the diagnostics segment, particularly in China, and emphasized the importance of M&A to enhance growth [82][90] Question: Acceleration of top-line growth in the second half - Management indicated that new product launches and favorable comparisons to previous year performance will drive growth acceleration [102][106] Question: Gross margin expectations amid tariff impacts - Management confirmed that tariffs would primarily affect gross margins, but favorable FX movements could help offset some impacts [108] Question: Plans for seeking exemptions from tariffs - Management stated that while they are engaged with industry associations, they do not rely on hope for tariff exemptions and are focused on data-driven strategies [130][132] Question: Diversified model and potential for unlocking value - Management reiterated the value of their diversified model and stated that they are continuously evaluating opportunities to create value without current plans for divestitures [138][140]

Core Insights - IM8 hosted an event called IM8 Vibrante to promote its vision of making elite wellness accessible to all, featuring nearly 150 attendees including wellness influencers and medical advisors [1][2] - The event highlighted IM8's commitment to blending science and holistic health, showcasing its flagship product, Daily Ultimate Essentials, which is designed to replace 16 different supplements [7] Company Overview - IM8 is co-founded by David Beckham and focuses on premium core nutrition, combining advanced science with natural ingredients to promote health [7] - The flagship product, Daily Ultimate Essentials, is NSF Certified for Sport, non-GMO, vegan, and free from common allergens, artificial flavors, colors, and sweeteners [7] Event Highlights - David Beckham shared his personal wellness journey and the positive impact of IM8 on his energy and focus [3] - A panel discussion featured experts discussing longevity and healthspan, emphasizing the importance of quality of life alongside lifespan [3] - Dr. Jim Green presented ongoing research on advanced aging in space, in collaboration with Oxford University and SpaceX [3] Community Engagement - The event underscored the strength of the IM8 ambassador and creator community, which plays a vital role in promoting wellness and engaging audiences [5] - Influencers from platforms like TikTok and Meta showcased their commitment to wellness, aligning with IM8's mission [5] Leadership Perspective - Danny Yeung, CEO of IM8, expressed pride in the progress made and the inspiring energy of the community at the event [6]